Oral mucositis

Oral Oncology

Volumn 46, Issue 6, 2010, Pages 452-456

  Raber Durlacher, Judith E ^a   Elad, Sharon ^b   Barasch, Andrei ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer; Chemotherapy; Graft versus Host Disease; Haematopoietic stem cell transplantation; Head and neck cancer; Mucosal barrier injury; Oral mucositis; Radiation; Toxicity; Ulceration

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORHEXIDINE; PALIFERMIN;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CRYOTHERAPY; DRUG CONTRAINDICATION; DRUG MEGADOSE; GENETIC PREDISPOSITION; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW LEVEL LASER THERAPY; MOUTH FLORA; MOUTH HYGIENE; MOUTH MUCOSA; MOUTH ULCER; MUCOSA INFLAMMATION; ORAL MUCOSITIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RADIATION DOSE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MOUTH MUCOSA; PAIN, INTRACTABLE; PRACTICE GUIDELINES AS TOPIC; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RISK FACTORS; STOMATITIS;

EID: 77952744823     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2010.03.012     Document Type: Review

References (49)

1. Pryor D.I., Poreddu S.V., Burmeister B.H., Guminsky A., Thomson D.B., Shepardson K., et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90 2 (2009) 172-176
2. Gerullis H., Bergmann L., Maute L., Elmer C., and Otto T. Experiences and practical conclusions concerning temsirolimus and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol 63 6 (2009) 1097-1102
3. Sonis S., Treister N., Chawla S., Demetri G., and Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of ripamycin in cancer patients. Cancer 116 1 (2010) 210-215
4. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M., Hauer-Jensen M., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 Suppl. 9 (2004) 1995-2025
5. Stiff P., Erder H., Bensinger W.I., Emmanouilides C., Gentile T., Isitt J., et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous bone marrow transplantation (HSCT). Bone Marrow Transplant 37 4 (2006) 393-401
6. Epstein J.B., Beaumont J.L., Gwede C.K., Murphy B., Garden A.S., Meridith R., et al. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer 109 9 (2007) 1914-1922
7. Peterson D.E., Keefe D.M., Hutchins R.D., and Schubert M.M. Alimentary tract mucositis in cancer patients: impact on terminology and assessment on research and clinical practice. Support Care Cancer 14 6 (2006) 499-504
8. Blijlevens N.M., Donnelly J.P., and de Pauw B.E. Mucosal barrier injury: biology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25 12 (2000) 1269-1278
9. Sonis S.T. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34 1 (1998) 39-43
10. Sonis S.T. The pathobiology of mucositis. Semin Oncol Nurs 20 1 (2004) 11-15
11. Scully C., Epstein J.B., and Sonis S.T. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 1, pathogenesis and prophylaxis of mucositis. Head Neck 25 12 (2003) 1057-1070
12. Vissink A., Burlage F.R., Spijkervet F.K.L., Jansma J., and Coppes R.P. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 14 3 (2003) 213-225
13. Sonis S.T. A biological approach to mucositis. J Support Oncol 2 1 (2004) 21-36
14. Barasch A., and Peterson D.E. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39 2 (2003) 91-100
15. Logan R.M. Advances in understanding of toxicities of treatment for head and neck cancer. Oral Oncol 45 10 (2009) 844-848
16. Sonis S.T. Regimen-related gastrointestinal toxicities in cancer patients. Curr Opin Support Palliative Care 4 1 (2010) 26-30
17. Takahashi K., Soga Y., Murayama Y., Udagawa M., Nishimoto H., Sugiura Y., et al. Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen. Support Care Cancer (2009) [Epub ahead of print]
18. Robien K., Schubert M.M., Bruemmer B., Lloid M.E., Potter J.D., and Ulrich C.M. Predictors of oral mucositis in patients receiving hematopoietic stem cell transplants for chronic myelogenous leukemia. J Clin Oncol 22 7 (2004) 1268-1275
19. Bogunia-Kubik K., Polak M., and Lange A. TNF polymorphisms are associated with toxic, but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 32 6 (2003) 617-622
20. Blijlevens N., Schwenkglenks M., Bacon P., D'Addio A., Einsele H., Maertens J., et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 26 9 (2008) 1519-1525
21. Bellm L.A., Epstein J.B., Rose-Red A., Martin P., and Fuchs H.J. Patient reports of complications of bone marrow transplantation. Support Care Cancer 8 1 (2000) 33-39
22. Rose-Ped A.M., Bellm L.A., Epstein J.B., Trotti A., Gwede C., and Fuchs H.J. Complications of radiation therapy for head and neck cancers: the patients' perspective. Cancer Nurs 25 6 (2002) 461-467
23. Elting L.S., Keefe D.M., Sonis S.T., Garden A.S., Spijkervet F.K., Barasch A., et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation and impact on quality of life. Cancer 113 10 (2008) 2704-2713
24. Murphy B.A., Beaumont J.L., Isitt J., Garden A.S., Gwede C.K., and Trotti A.M. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage 36 4 (2009) 522-532
25. Sonis S.T., Oster G., Fuchs H., Bellm L., Bradford W.Z., Edelsberg J., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19 8 (2001) 2201-2205
26. Elting L.S., Cooksley C., Chambers M., Cantor S.B., Manzullo E., and Rubenstein E.B. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 7 (2003) 1531-1539
27. Murphy B.A. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation. J Support Oncol 5 9, Suppl. 4 (2007) 13-21
28. Nonzee N.J., Dandade N.A., Markossian T., Agulnik M., Argiris A., Patel J.D., et al. Evaluating the supportive care costs of severe radio-chemotherapy-induced mucositis and pharyngitis. Cancer 113 6 (2009) 1446-1452
29. Blijlevens N.M.A., Logan R.M., and Netea M.G. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis. J Antimicrob Chemother 63 Suppl. 1 (2009) 36-40
30. McCann S., Schwenkglenks M., Bacon P., Einsele H., D'Addio A., Maertens J., et al. The prospective oral mucositis audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant 43 2 (2009) 141-147
31. Fanning S.R., Rybicki L., Kalaycio M., Andresen S., Kuczkowski E., Pohlman B., et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 135 3 (2006) 374-381
32. Cleeland C.S. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 37 (2007) 16-21
33. Miaskowski C., Aouizerat B.E., Dodd M., and Cooper B. Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. J Natl Cancer Inst Monogr 37 (2007) 39-46
34. Aprile G., Ramoni M., Keefe D., et al. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 112 2 (2009) 284-292
35. Schubert M.M. Oral manifestations of viral infections in immunocompromised patients. Curr Opin Dent 1 4 (1991) 384-397
36. Scully C., Epstein J.B., and Sonis S.T. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck 26 1 (2004) 77-84
37. Rubenstein E.B., Peterson D.E., Schubert M., Keefe D., McGuire D., Epstein J.B., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Cancer 100 Suppl. 9 (2004) 2026-2046
38. Keefe D.M., Schubert M.M., Elting L.S., Sonis S.T., Epstein J.B., Raber-Durlacher J.E., et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109 5 (2007) 820-831
39. Worthington H.V., Clarson J.E., and Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 4 (2007) CD000978
40. Worthington H.V., Clarson J.E., and Eden O.B. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2 (2007) CD001973
41. Bensinger W., Schubert M., Ang K.K., Brizel D., Brown E., Eilers J.G., et al. NCCN task force report. Prevention and management of mucositis in cancer care. J Natl Comp Canc Netw 6 Suppl. 1 (2008) S1-S21
42. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27 1 (2009) 127-145
43. Harris D.J., Eilers J., Harriman A., Cashavely B.J., and Maxwell C. Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs 12 1 (2008) 141-152
44. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 25 (2004) 2590-2598
45. Barasch A., Epstein J.B., and Tilashalski K. Palifermin for management of treatment-induced oral mucositis in cancer patients. Biologics: Targets Therapy 3 (2009) 111-116
46. Keefe D.M., Sonis S.T., and Bowen J.M. Emerging drugs for chemotherapy-induced mucositis. Exp Opinion Emerg Drugs 13 3 (2008) 511-522
47. Sonis S.T. The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45 12 (2009) 1015-1020
48. Epstein J.B., Elad S., Eliav E., Jurevic R., and Benoliel R. Orofacial pain in cancer patients: part II - clinical perspectives and management. J Dent Res 86 6 (2007) 506-518
49. Milstein D.M., Te Boome L.C., Cheung Y.W., Lindenboom J.A., van den Akker H.P., Biemond B.J., et al. Use of sidestream dark-field (SDF) imaging for assessing the effects of high-dose melphalan and autologous stem cell transplantation on oral mucosal microcirculation in myeloma patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109 1 (2010) 91-97